Hillary Bownik, MD
Gastroenterology · Kansas City, MONPI 1013147206
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $71,723 of the $84,646 with a category attached, or 84.7%. 31 manufacturers reported payments, led by Johnson & Johnson at 44.9% of the total. Among gastroenterology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $269.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$38K
- Janssen Scientific Affairs, LLC$26K
- AbbVie$8K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- Amgen$2K
- Bristol Myers Squibb$263
- plus $2K from 25 others
Across 32 payments — averaging $10,295 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$315K
- Takeda Pharmaceuticals U.S.A., Inc.$13K
- E.r. Squibb & Sons, L.L.C.$2K
What the payments were for
- Consulting fees$3,1254%
- Speaking & faculty fees$71,72385%
- Travel & lodging$2,5733%
- Food & beverage$7,1048%
- Education$400%
- Entertainment$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 63 | $38,025 |
| Janssen Scientific Affairs, LLC | 26 | $25,872 |
| AbbVie | 97 | $8,224 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $8,184 |
| Amgen | 3 | $2,445 |
| Bristol Myers Squibb | 19 | $263 |
| Celltrion USA Inc. | 12 | $209 |
| Merck | 10 | $186 |
| Sanofi | 6 | $151 |
| Pfizer | 6 | $101 |
| Lilly USA, LLC | 4 | $99 |
| Mauna Kea Technologies, Inc. | 2 | $94 |
| Boston Scientific | 1 | $86 |
| Fresenius Kabi USA, LLC | 4 | $85 |
| Daiichi Sankyo Inc. | 4 | $76 |
| QOL Medical, LLC | 3 | $72 |
| Organon | 4 | $66 |
| Phathom Pharmaceuticals, Inc. | 4 | $61 |
| AMAG Pharmaceuticals, Inc. | 3 | $46 |
| Novo Nordisk | 2 | $46 |
| Ardelyx, Inc. | 2 | $41 |
| Aimmune Therapeutics, Inc. | 2 | $39 |
| Nestle Healthcare Nutrition Inc. | 2 | $34 |
| Endo Pharmaceuticals Inc. | 2 | $30 |
| Ironwood Pharmaceuticals, Inc | 2 | $25 |
| Medtronic | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| La Jolla Pharmaceutical Company | 1 | $13 |
| Micro-tech Endoscopy USA, Inc. | 2 | $12 |
| Endogastric Solutions, Inc | 2 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$84,646 in reported general payments places this provider in the 95th percentile of 374 gastroenterology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 61 | $1,888,477 |
| Humira(Cf) PenAdalimumab | 60 | $606,111 |
| GattexTeduglutide | 12 | $556,290 |
| CreonLipase/Protease/Amylase | 20 | $92,890 |
| RinvoqUpadacitinib | 11 | $74,951 |
| ZenpepLipase/Protease/Amylase | 18 | $69,698 |
| XifaxanRifaximin | 11 | $24,929 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 263 | $17,232 |
| LinzessLinaclotide | 16 | $10,784 |
| TrulancePlecanatide | 12 | $6,665 |
| Mesalamine | 16 | $6,189 |
| Pantoprazole Sodium | 257 | $3,508 |
| Budesonide EcBudesonide | 22 | $3,002 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 17 | $2,787 |
| Balsalazide Disodium | 14 | $2,397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $38,025 | $1,888,47761 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $8,184 | $556,29012 claims |
| AbbVieCreon, Rinvoq, Linzess | $8,224 | $178,62447 claims |
| Aimmune Therapeutics, Inc.Zenpep | $39 | $69,69818 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $14 | $31,59323 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $85 | $3612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 374 gastroenterology providers in Missouri.
Other gastroenterology in Kansas City
- Laith Al MomaniKansas City$249K
- Ahmed SaeedKansas City$246K
- Tahar MahmoudiKansas City$114K
- Amit RastogiKansas City$63K
- Rajiv ChhabraKansas City$29K
- Bradley FreilichKansas City$26K
- Prashant PandyaKansas City$21K
- Syed JafriKansas City$20K
- Gregory MerrittKansas City$16K
- Gregory SayukSaint Louis$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.